Summary
The pharmacokinetics of direct oral anticoagulants (DOACs), which are similar to those
of low-molecular-weight heparin (LMWH), allow these substances to be substituted for
each other in routine clinical practice while maintaining the same frequency of administration.
Parenteral LMWH administration is mainly performed if oral DOAC administration is
either unsafe or impossible. The required waiting period prior to interventions or
surgery can be precisely determined for both applications. Where necessary, both substance
classes are monitored using similar laboratory tests.
General concomitant coagulation monitoring, as has been practised for many decades
using vitamin K antagonists, is not necessary during treatment with the new Xa and
thrombin inhibitors. If specific clinical situations (e.g. emergency surgery or interventions,
acute haemorrhage, acute organ failure) arise in patients undergoing treatment with
a DOAC, information about the patient‘s plasma drug level can aid the physician in
assessing the haemorrhage risk. As the DOACs act at a central position of the coagulation
system, they interfere with global coagulation tests, such as prothrombin time (PT;
Quick’s time / INR), activated partial thromboplastin time (aPTT) and thrombin time
(TT) (only thrombin inhibitors!) and specific physiologically based coagulation tests.
The changes in coagulation diagnostics depend on both the DOAC’s mode of action and
the corresponding half-life, as well as the time of tablet intake, the dosage and
the test system/ reagent used in the coagulation laboratory. In order to interpret
the results of haemostaseo-logical measurement, both the clinician and the laboratory
physician need to know which DOAC was taken and at what time.
In addition, the sensitivity (dose-response curve) of each test system used must be
considered. Under DOAC treatment, global coagulation assays can only provide estimated
(semi-quantitative) statements: If the prothrombin time (Quick’s time / INR), is in
the range of normal during rivaroxaban in-take (provided that a rivaroxaban-sensitive
reagent, e.g. Neoplastin Plus, was used in the laboratory), it can be assumed that
any clinically relevant residual effect of rivaroxaban in the patient’s plasma is
unlikely. During dabigatran intake, a trough aPTT >80 sec indicates an increased risk
of haemorrhage, while a TT in the range of normal indicates the absence of dabigatran
in the plasma.
For quantification of the plasma concentration of anti-Xa inhibitors, chromogenic
anti-Xa tests are available that are specifically calibrated to the substance being
tested. For quantification of the plasma dabigatran concentration, the calibrated
diluted thrombin time (Hemoclot® test) can be used. To date, however, measurement of drug concentrations has not formed
part of routine clinical practice, as the plasma concentrations measured cannot currently
be clinically interpreted for the individual patient. Overall, use of haemostaseological
laboratory methods for detecting DOACS must be planned according to the local situation
and repeatedly agreed (e.g. if the reagent is changed) between laboratory and clinic.
Keywords
Anticoagulation - pharmacokinetics - plasma level - laboratory monitoring
